Irritable Bowel Syndrome Pipeline Therapeutics Development - Review 2017


Posted May 26, 2017 by rahul0210

Irritable Bowel Syndrome - Pipeline Review, H1 2017 provides information on therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, MoA, RoA and molecule type.

 
Irritable Bowel Syndrome - Pipeline Review, H1 2017 report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects.
Inquire for Complete Irritable Bowel Syndrome Pipeline Review H1 2017 Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1010760
Description of Report:
Irritable Bowel Syndrome Pipeline Review H1 2017 report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Companies Analyzed In Report: 4D Pharma PLC, A. Menarini Industrie Farmaceutiche Riunite Srl, Alfa Wassermann SpA, Allergan Plc, Ardelyx Inc, Astellas Pharma Inc, CJ HealthCare Corp, ConSynance Therapeutics Inc, Cosmo Pharmaceuticals, Dong-A ST, Eisai Co Ltd, Enterome Bioscience SA, GlaxoSmithKline Plc, Innovative Med Concepts LLC, Ironwood Pharmaceuticals Inc, Kissei Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Napo Pharmaceuticals Inc, Pfizer, RaQualia Pharma Inc, RedHill Biopharma Ltd, SK Biopharmaceuticals Co Ltd, Sumitomo Dainippon Pharma Co Ltd, Synergy Pharmaceuticals Inc, Synthetic Biologics Inc, Vitality Biopharma Inc.
Get Discount on Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010760 (This report is available at up to 25% Discount till June 02nd 2017)
Drug Profile Discussed In Report: (celecoxib + famciclovir), ASP-7147, bedoradrine sulfate, Biologic for Irritable Bowel Syndrome with Constipation, Biologic for Irritable Bowel Syndrome with Diarrhea, Blautix, Canchew Plus, CJ-14199, crofelemer DR, CSTI-300, DA-6886, Drugs for Irritable Bowel Syndrome with Diarrhea, DSP-6952, E-2508, EB-420, GSK-3179106, ibodutant, linaclotide, linaclotide DR1, linaclotide DR2, lovastatin, LT-4006, LX-1033, ondansetron hydrochloride CR, ORP-101, PBF-677, plecanatide, PR-38, pregabalin, relenopride hydrochloride, rifamycin CR, rifaximin, RQ-00202730, RQ-00310941, Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine, solabegron hydrochloride, tenapanor hydrochloride, VB-210 .
Scope: The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome. The report reviews pipeline therapeutics for Irritable Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources. The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved Irritable Bowel Syndrome therapeutics and enlists all their major and minor projects. The report assesses Irritable Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome.
Direct Purchase This Report at http://www.reportsnreports.com/purchase.aspx?name=1010760 .
Report helps to Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome. Identify potential new clients or partners in the target demographic. Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics. Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Major Table OF Content
• Number of Products under Development for Irritable Bowel Syndrome, H1 2017 14
• Number of Products under Development for Irritable Bowel Syndrome - Comparative Analysis, H1 2017 15
• Number of Products under Development by Companies, H1 2017 16
• Number of Products under Development by Companies, H1 2017 (Contd..1) 17
• Number of Products under Development by Companies, H1 2017 (Contd..2) 18
• Number of Products under Investigation by Universities/Institutes, H1 2017 19
• Comparative Analysis by Late Stage Development, H1 2017 20
• Comparative Analysis by Clinical Stage Development, H1 2017 21
• Comparative Analysis by Early Stage Development, H1 2017 22
• Products under Development by Companies, H1 2017 23
• Products under Development by Companies, H1 2017 (Contd..1) 24
• Products under Development by Companies, H1 2017 (Contd..2) 25
• Products under Investigation by Universities/Institutes, H1 2017 26.
About Us:
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By ReportnRepors
Website ReportnRepors
Business Address Pune
Country India
Categories Biotech , Health , News
Tags drugs , irritable bowel syndrome , pipelien , therapeutics
Last Updated May 26, 2017